Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...
I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...
BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development
China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...
PackGene and SineuGene Partner on ALS Gene Therapy Research
China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...
China Establishes Leadership Group to Combat Drug-Related Crimes
China’s State Council executive body released a notification regarding the establishment of a leadership group...
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from...
Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study
China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient...
ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion
Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...
Ascletis Pharma Files IND Application for ASC10 with US FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...
MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...
Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...
Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion
China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...
Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...